The purpose of this study is to evaluate safety of the study device and study device performance in patients presenting with severe aortic stenosis who are considered to be high risk for open surgical repair.
A single arm, prospective, multicenter, non-randomized, and open trial, up to 5 years follow-up with the Symetis ACURATE TA™ which is an aortic bioprosthesis for minimal invasive implantation vie transapical access to treat patients with severe symptomatic aortic stenosis where conventional aortic valve replacement (AVR) via open heart surgery is considered to be associated with high surgical risk for evaluating safety and performance of the implantation and safety at 30-D follow-up.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
50
ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
Kerckhoff Klinik GmbH
Bad Nauheim, Germany
Universitätsklinikum Hamburg-Eppendorf Klinik für Herz-und Gefässchirurgie
Essen, Germany
Universitätsklinikum Essen Westdeutsches Herzzentrum Essen
Essen, Germany
Klinik für Herzchirurgie GmbH
Karlsruhe, Germany
Freedom from all-cause mortality at 30 day Follow Up
The primary study objective is to evaluate the safety of the ACURATE™ Transapical Aortic Bioprosthesis at 30 days post-procedure in patients presenting with severe aortic valve stenosis at high risk for conventional AVR surgery.
Time frame: 30-Day Follow-up
Freedom from all-cause mortality at 12 months Follow Up
The primary study objective is to evaluate the safety of the ACURATE™ Transapical Aortic Bioprosthesis at 12 months post-procedure in patients presenting with severe aortic valve stenosis at high risk for conventional AVR surgery.
Time frame: 12 months Follow-Up
Rate of Major Adverse Valve-Related Events (MAVRE) at 30 days and at 12 month follow up related to the study device as defined as;
2.1 Structural valve deterioration 2.2 Non-structural dysfunction of the implanted study device 2.3 Valve thrombosis, embolism, bleeding event 2.4 Operated valve endocarditis 2.5 Re-intervention on the implanted device 2.6 Valve-related mortality 2.7 Need for new permanent pacemaker or defibrillator within 14 days
Time frame: 30-Days and at 12 Months Follow-up
Rate of Major Adverse Cardiac and Cerebrovascular-Related Events (MACCE) at 30 days and at 12 Month and defined as cardiovascular death, myocardial infarction and stroke.
Defined as cardiovascular death, myocardial infarction and stroke
Time frame: 30-Day and 12-Month
Functional Improvement from baseline
per NYHA functional classification
Time frame: 30-Days and 12-Month Follow-up
Procedural success
defined as stable study device placement at intended site and adequate device functioning immediately post-implantation, confirmed by angiography and echocardiography as assessed at a Core Lab and without intraprocedural mortality.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Herzzentrum Leipzig GmbH
Leipzig, Germany
Time frame: 24 hours Post-Procedure
Device success at 30 Days and 12 Month follow-up as defined as adequate functioning of the study device as confirmed by angiography and/or echocardiography as assessed at a CoreLab.
Device success at 30 Days and 12 Month follow-up as defined as adequate functioning of the study device as confirmed by angiography and/or echocardiography as assessed at a CoreLab. The following datapoints will be analyzed: 6.1 Effective orifice area and index (EOA/EOAI) 6.2 Transvalvular Gradients (Peak and mean) 6.3 Paravalvular and intravalvular (Central) leaks 6.4 Aortic Insufficiency 6.5 LV function and hemodynamics 6.6 Valve function and morphology
Time frame: 30-Day and 12-Month Follow-up